S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Closing prices for crude oil, gold and other commodities
Comprehensive Analysis of PayPal Stock
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Closing prices for crude oil, gold and other commodities
Comprehensive Analysis of PayPal Stock
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Closing prices for crude oil, gold and other commodities
Comprehensive Analysis of PayPal Stock
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Closing prices for crude oil, gold and other commodities
Comprehensive Analysis of PayPal Stock
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup

Pieris Pharmaceuticals (PIRS) Competitors

$0.14
-0.01 (-6.45%)
(As of 04/19/2024 ET)

PIRS vs. AYTU, AVTX, ORGS, NRBO, TLPH, NERV, COCP, VBIV, TRAW, and KPRX

Should you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include Aytu BioPharma (AYTU), Avalo Therapeutics (AVTX), Orgenesis (ORGS), NeuroBo Pharmaceuticals (NRBO), Talphera (TLPH), Minerva Neurosciences (NERV), Cocrystal Pharma (COCP), VBI Vaccines (VBIV), Traws Pharma (TRAW), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical preparations" industry.

Pieris Pharmaceuticals vs.

Aytu BioPharma (NASDAQ:AYTU) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. Pieris Pharmaceuticals' average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score.

Company Overall Sentiment
Aytu BioPharma Neutral
Pieris Pharmaceuticals Neutral

Pieris Pharmaceuticals received 23 more outperform votes than Aytu BioPharma when rated by MarketBeat users. However, 67.11% of users gave Aytu BioPharma an outperform vote while only 62.05% of users gave Pieris Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Aytu BioPharmaOutperform Votes
255
67.11%
Underperform Votes
125
32.89%
Pieris PharmaceuticalsOutperform Votes
278
62.05%
Underperform Votes
170
37.95%

Aytu BioPharma has a beta of -1.21, suggesting that its stock price is 221% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

Aytu BioPharma has higher revenue and earnings than Pieris Pharmaceuticals. Aytu BioPharma is trading at a lower price-to-earnings ratio than Pieris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aytu BioPharma$107.40M0.14-$17.05M-$4.04-0.69
Pieris Pharmaceuticals$42.81M0.34-$24.54M-$0.28-0.52

Aytu BioPharma currently has a consensus price target of $5.00, suggesting a potential upside of 79.21%. Given Pieris Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Aytu BioPharma is more favorable than Pieris Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aytu BioPharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Pieris Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Aytu BioPharma has a net margin of -18.27% compared to Aytu BioPharma's net margin of -57.33%. Pieris Pharmaceuticals' return on equity of -41.00% beat Aytu BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Aytu BioPharma-18.27% -41.00% -10.87%
Pieris Pharmaceuticals -57.33%-90.17%-38.12%

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 40.1% of Pieris Pharmaceuticals shares are held by institutional investors. 4.3% of Aytu BioPharma shares are held by insiders. Comparatively, 8.9% of Pieris Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Aytu BioPharma beats Pieris Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PIRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PIRS vs. The Competition

MetricPieris PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$14.35M$6.47B$4.84B$7.32B
Dividend YieldN/A3.13%2.93%3.99%
P/E Ratio-0.526.95174.4114.79
Price / Sales0.34299.382,456.8581.89
Price / CashN/A28.6246.2534.42
Price / Book0.545.394.564.15
Net Income-$24.54M$143.87M$103.85M$214.00M
7 Day Performance-15.57%-6.75%-4.48%-3.51%
1 Month Performance-30.95%-9.80%-6.67%-5.50%
1 Year Performance-82.53%-5.47%7.75%3.54%

Pieris Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AYTU
Aytu BioPharma
2.4242 of 5 stars
$2.92
+9.0%
$5.00
+71.2%
+2.2%$16.26M$107.40M-0.72150
AVTX
Avalo Therapeutics
0.2813 of 5 stars
$15.94
+4.6%
N/A-98.4%$16.42M$1.92M-0.0320Analyst Upgrade
Gap Down
ORGS
Orgenesis
2.0878 of 5 stars
$0.50
flat
N/A-55.3%$15.94M$36.03M-0.55167Gap Down
NRBO
NeuroBo Pharmaceuticals
0.8473 of 5 stars
$3.40
-3.7%
N/A-39.8%$16.69MN/A0.002Gap Up
TLPH
Talphera
1.25 of 5 stars
$1.02
flat
$6.00
+488.2%
N/A$17.31M$650,000.00-0.6915
NERV
Minerva Neurosciences
3.1239 of 5 stars
$2.50
+3.3%
$11.00
+340.0%
-19.0%$17.48MN/A-0.549News Coverage
COCP
Cocrystal Pharma
2.5751 of 5 stars
$1.46
+3.5%
$10.00
+584.9%
-40.7%$14.85MN/A-0.7312Gap Up
VBIV
VBI Vaccines
1.2508 of 5 stars
$0.62
+6.9%
N/A-81.5%$14.69M$1.08M-0.05190Analyst Report
TRAW
Traws Pharma
0 of 5 stars
$0.70
-2.8%
N/AN/A$14.62M$230,000.00-0.76N/APositive News
KPRX
Kiora Pharmaceuticals
2.6476 of 5 stars
$0.55
-1.8%
$7.00
+1,173.2%
-86.7%$14.44MN/A0.0012News Coverage

Related Companies and Tools

This page (NASDAQ:PIRS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners